HEALTH TECHNOLOGY ASSESSMENT FOR DECISION MAKERS

July 20 – 22, 2011 • University of Toronto

AN INTENSIVE COURSE ON PRAGMATIC HTA TOOLS FOR DECISION MAKERS, INDUSTRY REPRESENTATIVES, AND RESEARCHERS
WHO SHOULD TAKE THIS COURSE?

• Individuals using health technology assessments and making resource allocation decisions relating to drugs, devices, and programs

• Decision-makers, practitioners, and researchers who need to understand the strengths and weaknesses of using HTA for policy making

KEY FEATURES

• Intensive three-day program
• Theory bursts in lecture format to introduce and explain key concepts
• Interactive sessions (small group learning and computer labs) to explore illustrative cases

OBJECTIVES

By the end of the course, participants will be able to:

• Explore the standards for clinical evidence
• Review and appraise measures of evidence
• Explore cost-effectiveness analysis
• Assess and interpret cost-effective analyses
• Explore the social and ethical issues in HTA
• Identify ways to address social and ethical issues through HTA

DATE & LOCATION

Date: July 20–22, 2011
Time: 9am–5pm
Location: University of Toronto
Health Sciences Building, Room 208
155 College Street, Toronto ON
Day 1: Clinical Evidence

Day 1 will examine the nature of clinical evidence. We will examine how we know that an intervention is effective; including reviewing the standards for evidence and the strengths and weaknesses of alternative study designs such as randomized controlled trials and observational research. We will also review common measures of effectiveness so that readers of the medical literature can understand the types of outcomes included in clinical research studies.

Day 2: Value (Cost-Effectiveness Analysis)

Day 2 will explore the idea of value- the relationship between cost and health benefit. Participants will learn the key concepts and designs in cost effectiveness analysis, how to perform a simple analysis, and how to appraise and interpret cost effectiveness analyses that are part of health technology assessments. The day will be built around real-world cases, but will include theory and practical exercises.

Day 3: Social and Ethical Issues

Day 3 will examine the social and ethical issues that arise in HTA and how these can be explicitly addressed. Health technologies raise social and ethical issues that may not be fully captured in assessments of clinical and cost effectiveness. Historically, these issues have only been identified in a few extreme cases. Today, there is increased interest in making social and ethical issues in HTA more transparent. Through lectures and interactive small group sessions, we will explore why clinical and cost effectiveness methods are not always enough, and how additional evidence or decision-making can improve HTA recommendations.

For detailed course descriptions, please visit [www.theta.utoronto.ca/static/education/?hti](http://www.theta.utoronto.ca/static/education/?hti).
FACULTY

The Institute features leading HTA faculty from the Department of Health Policy, Management and Evaluation at the University of Toronto including:

Ahmed Bayoumi, MD, MSc | Director, Clinical Epidemiology, UofT; Associate Professor, Medicine, UofT; CIHR/Ontario MOHLTC Applied Chair in Health Services and Policy Research; Member, Committee to Evaluate Drugs Cancer Care Ontario Subcommittee, Ontario MOHLTC

Yvonne Bombard, PhD | Post-Doctoral Fellow, Public Health, Division of Health Policy and Administration, Yale University and Centre for Health Policy and Outcomes and Clinical Cancer Genetics, Memorial Sloan Kettering Cancer Centre

Peter C. Coyte, PhD | Health Economics Professor, HPME, UofT and CHSRF/CIHR Chair in Health Services Research 2000–2010

Allan Grill, MD, CCFP, MPH | Assistant Professor, Family and Community Medicine and Dalla Lana School of Public Health, UofT; Chair, Committee to Evaluate Drugs Cancer Care Ontario Subcommittee, Ontario MOHLTC

Joseph S. Kim, PhD | Assistant Professor, Medicine, UofT; Division of Nephrology and Kidney Transplant Program, University Health Network

Murray Krahn, MD, MSc | F. Norman Hughes Chair in Pharmacoeconomics, UofT; Director, Toronto Health Economics and Technology Assessment Collaborative (THETA); Member, Ontario Health Technology Advisory Committee

Audrey Laporte, PhD | Associate Professor, HPME, UofT

Fiona Miller, PhD | Associate Professor, HPME, UofT and CIHR-HISPR New Investigator Awardee

Beate Sander, RN, MBA, MEdDec | Health Economist, Ontario Agency for Health Protection and Promotion

Prakesh Shah, MD, MSc, MBBS, DCH, MRCP, FRCPC | Associate Professor, Paediatrics and HPME, UofT

For a full faculty listing, please visit www.theta.utoronto.ca/static/education/?hti.

FEE & REGISTRATION

Course Fee: $1130 CDN ($1000 + 13% HST) > Registration Deadline: July 1, 2011 > Maximum Registration: 40 participants

You can register online or send a completed registration form (available for download from our website) via mail. The course fee includes tuition, all study materials, breakfasts, lunches, and snacks. Please issue a cheque payable to the University of Toronto and send by the registration deadline. Note that registration is finalized with payment.

CONTACT INFORMATION

For more information, please contact:

Anne Louise Montgomery | Department of Health Policy, Management & Evaluation | University of Toronto
155 College Street, Suite 425 | Toronto, Ontario M5T 3M6
p. 416-978-2067 | f. 416-978-7350 | e. annelouise.pontigon@utoronto.ca

http://www.theta.utoronto.ca/static/education/?hti